Impact of FDA actions, DTCA, and public information on the market for pain medication

W. David Bradford, Andrew Nathan Kleit

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most important classes of prescription drugs used by primary care physicians to manage pain. The NSAID class of products has a somewhat controversial history, around which a complex regulatory and informational environment has developed. This history includes a boxed warning mandated by the Food and Drug Administration (FDA) for all NSAIDs in 2005. We investigate the impact that various information shocks have had on the use of prescription medications for pain in primary care in the USA. We accomplish this by extracting data on nearly 600 000 patients from a unique nationwide electronic medical record database and estimate the probability of any active prescription for the four types of pain medications as a function of FDA actions, advertising, media coverage, and patient characteristics. We find that even after accounting for multiple sources of information, the FDA label changes and boxed warnings had a significant effect on pain medication prescribing. The boxed warning did not have the same impact on the use of all NSAID inhibitors. We find that the boxed warning reduced the use of NSAID COX-2 inhibitor use, which was the focus of much of the press attention. In contrast, however, the warning actually increased the use of non-COX-2 NSAID inhibitors. Thus, the efficacy of the FDA's black box warning is clearly mixed.

Original languageEnglish (US)
Pages (from-to)859-875
Number of pages17
JournalHealth Economics (United Kingdom)
Volume24
Issue number7
DOIs
StatePublished - Jan 1 2015

Fingerprint

Drug Labeling
United States Food and Drug Administration
Anti-Inflammatory Agents
Pain
Pharmaceutical Preparations
Prescriptions
History
Prescription Drugs
Electronic Health Records
Cyclooxygenase 2 Inhibitors
Primary Care Physicians
Shock
Primary Health Care
Databases

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

@article{70bb85ee6e004abd903314ec65548928,
title = "Impact of FDA actions, DTCA, and public information on the market for pain medication",
abstract = "Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most important classes of prescription drugs used by primary care physicians to manage pain. The NSAID class of products has a somewhat controversial history, around which a complex regulatory and informational environment has developed. This history includes a boxed warning mandated by the Food and Drug Administration (FDA) for all NSAIDs in 2005. We investigate the impact that various information shocks have had on the use of prescription medications for pain in primary care in the USA. We accomplish this by extracting data on nearly 600 000 patients from a unique nationwide electronic medical record database and estimate the probability of any active prescription for the four types of pain medications as a function of FDA actions, advertising, media coverage, and patient characteristics. We find that even after accounting for multiple sources of information, the FDA label changes and boxed warnings had a significant effect on pain medication prescribing. The boxed warning did not have the same impact on the use of all NSAID inhibitors. We find that the boxed warning reduced the use of NSAID COX-2 inhibitor use, which was the focus of much of the press attention. In contrast, however, the warning actually increased the use of non-COX-2 NSAID inhibitors. Thus, the efficacy of the FDA's black box warning is clearly mixed.",
author = "Bradford, {W. David} and Kleit, {Andrew Nathan}",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/hec.3067",
language = "English (US)",
volume = "24",
pages = "859--875",
journal = "Health Economics",
issn = "1057-9230",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

Impact of FDA actions, DTCA, and public information on the market for pain medication. / Bradford, W. David; Kleit, Andrew Nathan.

In: Health Economics (United Kingdom), Vol. 24, No. 7, 01.01.2015, p. 859-875.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of FDA actions, DTCA, and public information on the market for pain medication

AU - Bradford, W. David

AU - Kleit, Andrew Nathan

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most important classes of prescription drugs used by primary care physicians to manage pain. The NSAID class of products has a somewhat controversial history, around which a complex regulatory and informational environment has developed. This history includes a boxed warning mandated by the Food and Drug Administration (FDA) for all NSAIDs in 2005. We investigate the impact that various information shocks have had on the use of prescription medications for pain in primary care in the USA. We accomplish this by extracting data on nearly 600 000 patients from a unique nationwide electronic medical record database and estimate the probability of any active prescription for the four types of pain medications as a function of FDA actions, advertising, media coverage, and patient characteristics. We find that even after accounting for multiple sources of information, the FDA label changes and boxed warnings had a significant effect on pain medication prescribing. The boxed warning did not have the same impact on the use of all NSAID inhibitors. We find that the boxed warning reduced the use of NSAID COX-2 inhibitor use, which was the focus of much of the press attention. In contrast, however, the warning actually increased the use of non-COX-2 NSAID inhibitors. Thus, the efficacy of the FDA's black box warning is clearly mixed.

AB - Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most important classes of prescription drugs used by primary care physicians to manage pain. The NSAID class of products has a somewhat controversial history, around which a complex regulatory and informational environment has developed. This history includes a boxed warning mandated by the Food and Drug Administration (FDA) for all NSAIDs in 2005. We investigate the impact that various information shocks have had on the use of prescription medications for pain in primary care in the USA. We accomplish this by extracting data on nearly 600 000 patients from a unique nationwide electronic medical record database and estimate the probability of any active prescription for the four types of pain medications as a function of FDA actions, advertising, media coverage, and patient characteristics. We find that even after accounting for multiple sources of information, the FDA label changes and boxed warnings had a significant effect on pain medication prescribing. The boxed warning did not have the same impact on the use of all NSAID inhibitors. We find that the boxed warning reduced the use of NSAID COX-2 inhibitor use, which was the focus of much of the press attention. In contrast, however, the warning actually increased the use of non-COX-2 NSAID inhibitors. Thus, the efficacy of the FDA's black box warning is clearly mixed.

UR - http://www.scopus.com/inward/record.url?scp=84930377777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930377777&partnerID=8YFLogxK

U2 - 10.1002/hec.3067

DO - 10.1002/hec.3067

M3 - Article

C2 - 25059655

AN - SCOPUS:84930377777

VL - 24

SP - 859

EP - 875

JO - Health Economics

JF - Health Economics

SN - 1057-9230

IS - 7

ER -